A Pilot Trial of Topical Capsaicin Cream for Treatment of Cannabinoid Hyperemesis Syndrome

被引:21
|
作者
Dean, Diana J. [1 ,2 ]
Sabagha, Noor [1 ]
Rose, Kaitlin [1 ,3 ]
Weiss, Alexander [1 ]
France, John [4 ]
Asmar, Timothy [1 ]
Rammal, Jo-Ann [1 ]
Beyer, Margaret [1 ]
Bussa, Rebecca [1 ]
Ross, Jacob [1 ]
Chaudhry, Kaleem [1 ]
Smoot, Thomas [5 ]
Wilson, Kathleen [1 ]
Miller, Joseph [1 ,4 ]
机构
[1] Henry Ford Hosp, Dept Emergency Med, Detroit, MI 48202 USA
[2] Michigan Poison Ctr, Detroit, MI USA
[3] Cent Michigan Univ, Coll Med, Mt Pleasant, MI 48859 USA
[4] Wayne State Univ, Detroit, MI 48202 USA
[5] Frederick Mem Hosp, Frederick, MD USA
关键词
EMERGENCY-DEPARTMENT; OSTEOARTHRITIS; SEVERITY; EFFICACY; NAUSEA;
D O I
10.1111/acem.14062
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objectives Patients with cannabinoid hyperemesis syndrome (CHS) present frequently to the emergency department. Previous case studies suggest dramatic symptomatic improvement with topical capsaicin treatment. This exploratory study examined the potential effectiveness of topical capsaicin in patients with nausea and vomiting due to a suspected CHS exacerbation. Methods This was a double-blind, randomized placebo-controlled pilot trial. Adults who presented with vomiting suspected to be from CHS were eligible for enrollment. We excluded pregnant women and those with resolution of symptoms. Following randomization, topical 0.1% capsaicin or placebo cream was applied to the anterior abdomen in a uniform manner. The primary outcome was the severity of nausea on a visual analog scale (VAS) of 0 to 10 cm assessed at 30 minutes. Secondary outcomes were adverse events, occurrence of posttreatment vomiting, nausea by VAS at 60 minutes, and hospital admission. Results This pilot trial enrolled 30 patients, 17 in the capsaicin arm and 13 in the placebo arm. One patient in the capsaicin arm did not tolerate treatment due to skin irritation. Mean +/- SD nausea severity at 30 minutes was 4.1 +/- 2.3 cm in the capsaicin arm and 6.1 +/- 3.3 cm in the placebo arm (difference = -2.0 cm, 95% confidence interval [CI] = 0.2 to -4.2 cm). At 60 minutes, mean +/- SD nausea severity was 3.2 +/- 3.2 cm versus 6.4 +/- 2.8 cm (difference = -3.2 cm, 95% CI = -0.9 to -5.4 cm). The percent reduction in nausea at 60 minutes from baseline was 46.0% in the capsaicin arm and 24.9% in the placebo arm (difference = 21.1%, 95% CI = -5.6% to 47.9%). A higher proportion of capsaicin group patients (29.4% vs. 0%) had complete resolution of nausea (relative risk = 3.4, 95% CI = 1.6 to 7.1). Conclusion In this pilot trial, the application of topical capsaicin cream was associated with a significant reduction in nausea at 60 minutes but not at 30 minutes and provided more complete relief of nausea.
引用
收藏
页码:1166 / 1172
页数:7
相关论文
共 50 条
  • [31] Cannabinoid hyperemesis syndrome, a treatment discussion
    Ramos-Perdigues, S.
    Gordillo, M. J.
    Caballero, C.
    Latorre, S.
    Boned, S. V.
    Guisado, M.
    De Almuedo, M.
    Torres, P.
    Sanchez, M. T.
    Contreras, E.
    Fernandez, A.
    Esmeralda, G.
    Sanchez, E.
    Segura, M.
    Torres, C.
    Herrero, G.
    Tur, M.
    Merino, C.
    EUROPEAN PSYCHIATRY, 2017, 41 : S318 - S318
  • [32] TREATMENT OF AQUAGENIC PRURITUS WITH TOPICAL CAPSAICIN CREAM
    LOTTI, T
    TEOFOLI, P
    TSAMPAU, D
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1994, 30 (02) : 232 - 235
  • [33] CANNABINOID HYPEREMESIS SYNDROME Cannabinoid hyperemesis syndrome: implications for pregnancy
    Braillon, Alain
    Bewley, Susan
    BMJ-BRITISH MEDICAL JOURNAL, 2019, 366
  • [34] Efficacy of topical capsaicin for cannabinoid hyperemesis syndrome in a pediatric and adult emergency department (Vol 49, pg 343, 2021)
    Kum, Vivian
    Bell, Adrienne
    Fang, Wei
    VanWert, Elizabeth
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2024, 79 : 233 - 233
  • [35] The utility of droperidol in the treatment of cannabinoid hyperemesis syndrome
    Lee, Carl
    Greene, Shaun L.
    Wong, Anselm
    CLINICAL TOXICOLOGY, 2019, 57 (09) : 773 - 777
  • [36] CANNABINOID HYPEREMESIS SYNDROME: A REVIEW OF THE PRESENTATION AND TREATMENT
    Leu, Nathaniel
    Routsolias, Joanne C.
    JOURNAL OF EMERGENCY NURSING, 2021, 47 (03) : 483 - 486
  • [37] Haloperidol as a treatment option in cannabinoid hyperemesis syndrome
    Stawinski, Peter
    Dziadkowiec, Karolina
    Sah, Amit
    Miller, Akiva Marcus
    GASTROENTEROLOGY REVIEW-PRZEGLAD GASTROENTEROLOGICZNY, 2022, 17 (04): : 342 - 343
  • [38] Cannabinoid hyperemesis syndrome - recognition, diagnosis and treatment
    Rehman, Ajaz-Ur
    Pervaiz, Amjadali
    Narayan, Manoj
    Saqib, Sarah
    PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2019, 23 (01) : 13 - 15
  • [39] Acute Treatment of Adolescent Cannabinoid Hyperemesis Syndrome With Haloperidol, Lorazepam, and/or Capsaicin: A Single Institution Case Series
    Brown, Jerry M.
    Wilsey, Michael J.
    Dhana, Leila
    Lonsdale, Hannah
    JOURNAL OF PSYCHIATRIC PRACTICE, 2023, 29 (05) : 354 - 358
  • [40] Haloperidol, a Novel Treatment for Cannabinoid Hyperemesis Syndrome
    Witsil, Joanne C.
    Mycyk, Mark B.
    AMERICAN JOURNAL OF THERAPEUTICS, 2017, 24 (01) : E64 - E67